-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Abcam (NASDAQ:ABCM) Given New GBX 2,200 Price Target at Royal Bank of Canada
Abcam (NASDAQ:ABCM) Given New GBX 2,200 Price Target at Royal Bank of Canada
Abcam (NASDAQ:ABCM – Get Rating) had its price target lifted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research report released on Wednesday, The Fly reports.
Separately, Panmure Gordon upgraded shares of Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
Get Abcam alerts:Abcam Price Performance
Shares of ABCM stock opened at $16.17 on Wednesday. The firm has a fifty day moving average of $14.85 and a 200-day moving average of $15.54. Abcam has a 12-month low of $12.54 and a 12-month high of $24.00.
Institutional Investors Weigh In On Abcam
Several large investors have recently made changes to their positions in the stock. Advisor Group Holdings Inc. increased its holdings in Abcam by 20.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company's stock worth $138,000 after buying an additional 999 shares during the last quarter. TD Asset Management Inc. lifted its stake in Abcam by 63.0% in the fourth quarter. TD Asset Management Inc. now owns 72,773 shares of the company's stock valued at $1,714,000 after acquiring an additional 28,130 shares during the last quarter. Bank of Montreal Can lifted its stake in Abcam by 0.9% in the fourth quarter. Bank of Montreal Can now owns 105,928 shares of the company's stock valued at $2,525,000 after acquiring an additional 956 shares during the last quarter. 2Xideas AG acquired a new stake in Abcam in the fourth quarter valued at $16,691,000. Finally, HM Payson & Co. acquired a new stake in Abcam in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 11.82% of the company's stock.About Abcam
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Read More
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
Abcam (NASDAQ:ABCM – Get Rating) had its price target lifted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research report released on Wednesday, The Fly reports.
據The Fly報道，在週三發佈的一份研究報告中，加拿大皇家銀行將Abcam(納斯達克：ABCM-GET評級)的目標價從1,700英鎊(20.54美元)上調至2,200英鎊(26.58美元)。
Separately, Panmure Gordon upgraded shares of Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
另外，Panmure Gordon在9月5日星期一的一份報告中將Abcam的股票評級從持有評級上調為買入評級。
Abcam Price Performance
Abcam性價比
Shares of ABCM stock opened at $16.17 on Wednesday. The firm has a fifty day moving average of $14.85 and a 200-day moving average of $15.54. Abcam has a 12-month low of $12.54 and a 12-month high of $24.00.
週三，ABCM的股票開盤報16.17美元。該公司的50日移動均線切入位為14.85美元，200日移動均線切入位為15.54美元。Abcam的12個月低點為12.54美元，12個月高位為24.00美元。
Institutional Investors Weigh In On Abcam
機構投資者在Abcam上發表看法
About Abcam
關於abcam
(Get Rating)
(獲取評級)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Abcam plc是一家生命科學公司，專注於識別、開發和分發用於科學研究、診斷和藥物發現的試劑和工具。它的主要產品包括一抗和二抗；結合抗體和結合試劑盒；單鏈和多重免疫分析；包括細胞因子的蛋白質和多肽；編輯的細胞系和裂解產物；以及各種其他產品，包括細胞活動試劑盒、miRNA試劑盒、生物化學品和細胞信號途徑工具。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
- 免費獲取關於abcam(ABCM)的StockNews.com研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 健康飲料製造商Celsius能否超越其Monster競爭對手？
- 具有有趣內幕活動的四隻廉價股票
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
接收abcam日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Abcam和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧